| Interagency Nonhuman Primate Repurposing Working Group |
Committee, Work group, Advisory group, or Task Force |
CDC |
OD/DPCPSI/ORIP |
This working group is exploring possible ways to efficiently re-use research animals. |
| Interagency Oncology Task Force Fellowship: Tracks 3 and 4 |
Training Initiative |
FDA |
NCI |
The objective of the Interagency Oncology Taskforce Fellowship Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Track 3 will train postdocs in the aspects of research and review of medical product development process to facilitate the movement of drugs, biologics, and devices from the bench to the bedside. Fellows will receive formal training and mentoring in the relevant federal statutes, regulations, principles, and practices of FDA medical product review, including issues related to product development, e.g., manufacturing processes, production, purification, characterization, testing, quality control, and quality assurance, understanding the biology, chemistry, pharmacoepidemiology, manufacturing, postmarketing surveillance, and mechanism of action/pathogenesis of disease. Track 4 of this fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines. |
| Interagency Oncology Taskforce Fellowship: Track 1 |
Research Initiative |
FDA |
NCI |
Also Training Initiative.The Interagency Oncology Task Force Fellowship (IOTF) program trains scientists in research and research-related regulatory review, policies, and regulations to develop a skill set that bridges the two disparate processes. This track will train physicians currently participating in the NIH Hematology Oncology Fellowship in aspects of clinical trials methodology and analysis, epidemiology, clinical aspects of medical product development, and regulation, as it relates to clinical research to facilitate the movement of drugs, biologics, and devices from the basic bench science to commercialization.Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind. |
| Interagency Pain Research Coordinating Committee (IPRCC) |
Committee, Work group, Advisory group, or Task Force |
AHRQ, FDA |
NCCIH, NIDA, NIDCR, NINDS, NINR |
The Interagency Pain Research Coordinating Committee (IPRCC) is a Federal advisory committee created by the Department of Health and Human Services to enhance pain research efforts and promote collaboration across the government, with the ultimate goals of advancing the fundamental understanding of pain and improving pain-related treatment strategies. |
| Interagency Pediatric Surge Working Group |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, HRSA |
NICHD |
The interagency working group meets weekly to discuss pressing surges and opportunities as it relates to addressing pediatric healthcare capacity, delivery and science. |
| Interagency Policy Committee on Social Determinants of Health (SDOH) |
Committee, Work group, Advisory group, or Task Force |
ACF, ACL, AHRQ, CDC, CMS, HRSA, SAMHSA |
NIAMS, NINR |
Convened by the White House Domestic Policy Council and the Office of Science and Technology Policy - the SDOH-IPC purpose is to support a Federal framework for a Coordinated Care Delivery Model to Address SDOH; Develop a White House Action Plan sharing guidance and potential policy levers to address Social Determinants of Health through data accessibility, integration and blending and braiding of funds. |
| Interagency Policy Council on Nutrition |
Committee, Work group, Advisory group, or Task Force |
CDC, HRSA |
NCI, NHLBI, NIDCR, NIDDK, OD/DPCPSI/ONR |
This working group is convened by the White House Domestic Policy Council (DPC) was charged with organizing the White House Conference on Hunger, Nutrition, and Health and developed and is implementing the Biden-Harris Administration National Strategy on Hunger, Nutrition, and Health. |
| Interagency Rehabilitation and Disability Research Portfolio |
Resource Development |
ACL, CDC |
NICHD |
IRAD is a searchable database of government funded research projects in the areas of disaiblity, independent living and rehabilitation research. The purpose of IRAD is to provide a publicly available resource that enables analysis of the federal research portfolio in disability, independent living, and rehabilitation research. This will aid in collaboration and coordination of research activities across federal agencies, as well as increase transparency and visibility for the public and legislative stakeholders. |
| Interagency Select Agent Review Group (ISARG) |
Committee, Work group, Advisory group, or Task Force |
BARDA, CDC |
NIAID, OD/OM, OD/OM/ORS, OD/OSP |
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Task Force for Trauma-Informed Care |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS, OCR, OMHA, SAMHSA |
NICHD, NIMH |
The Center for Mental Health Services (CMHS) leads the leads the Interagency Task to develop best practices for trauma-informed identification, referral, and support. The Interagency Task Force on Trauma-Informed Care (TIC Task Force) was established on October 13th, 2018, with the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018 (Public Law 115-271). The TIC Task Force is charged with identifying, evaluating, and making recommendations regarding: (1) best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma; and (2) ways in which federal agencies can better coordinate to improve the federal response to families impacted by substance use disorders and other forms of trauma. |